PharmaResearch
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
PharmaResearch makes injectable and topical products designed to help the body repair damaged tissue, using active ingredients extracted and purified from salmon DNA.
Its products, which include regenerative medicines, medical devices for skin improvement, and joint-injection treatments, are supplied to medical and aesthetic markets in South Korea and exported to Asia, Europe, and North America. Listed on KOSDAQ, South Korea's tech and small-cap board, the company's core business centres on its proprietary PDRN and PN technology platform, from which it develops products across pharmaceuticals, medical devices, and cosmetics.
Summary is AI-generated and may contain errors · figures from DART filings
PharmaResearch operates a subsidiary, PharmaResearch Bio, that runs a dedicated botulinum-toxin manufacturing facility and holds both domestic and export approvals for its toxin product.
PharmaResearch in five facts
What does PharmaResearch do?
PharmaResearch makes injectable and topical products designed to help the body repair damaged tissue, using active ingredients extracted and purified from salmon DNA.
Where is PharmaResearch listed and in which sector?
PharmaResearch (Korean name: 파마리서치) trades under KRX code 214450 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is PharmaResearch?
Its market capitalisation was US$2.1B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were PharmaResearch's latest annual revenue and operating profit?
For fiscal year 2025, PharmaResearch reported revenue of US$404.8M, operating profit of US$161.8M and net income of US$127M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 53.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 2
- Investor relations (IR) meetingSep 1
- Operating results (consolidated) (preliminary) (fair disclosure)
PharmaResearch filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$126M (+27.1% year on year), operating profit of US$46.7M (+19% year on year) and net income of US$39.5M (+33.7% year on year).
Earnings · Aug 7 - Operating results (consolidated) (preliminary) (fair disclosure)
PharmaResearch filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$100M (+25% year on year), operating profit of US$39.4M (+28.1% year on year) and net income of US$33.5M (+35.3% year on year).
Earnings · May 8 - Cash/in-kind dividend decision
PharmaResearch declared a cash dividend of US$2.56 per share.
Dividend · Feb 4 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
PharmaResearch reported consolidated results for FY2025: revenue of US$370M (+53% year on year), operating profit of US$148M (+70% year on year) and net income of US$118M (+91.8% year on year).
Earnings · Feb 4